Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer

BACKGROUND: A small proportion of patients with non-small cell lung cancer (NSCLC) experience objective clinical benefit after neoadjuvant programmed cell death 1 (PD-1) blockade. A neoadjuvant therapeutic regimen combining immune checkpoint blockade with chemotherapy might improve the treatment eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Chen, Yulong, Yan, Bo, Xu, Feng, Hui, Zhenzhen, Zhao, Gang, Liu, Jie, Zhang, Huan, Zeng, Ziqing, Zhang, Ran, Provencio, Mariano, Ren, Xiubao, You, Jian
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8182703/
https://ncbi.nlm.nih.gov/pubmed/34164269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-329
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados